Zero-Fluoroscopy May Match Standard VA Ablation - Summary - MDSpire

Zero-Fluoroscopy May Match Standard VA Ablation

Meta-analysis finds similar safety, success rate, recurrence risk vs. fluoroscopy-guided procedures.

  • By

  • Andrea Surnit

  • May 11, 2026

  • 3 min

Share

Objective:

To evaluate the safety and efficacy of zero-fluoroscopy catheter ablation compared to fluoroscopy-guided and nonzero-fluoroscopy catheter ablation in patients with ventricular arrhythmias.

Key Findings:
  • No statistically significant difference in acute procedural success between zero-fluoroscopy (ZF) and nonzero-fluoroscopy (NZF) techniques.
  • NZF group showed slightly higher recurrence rates compared to ZF group.
  • Procedural duration varied, with ZF showing shorter procedures in some studies.
  • Safety outcomes were similar between ZF and NZF, with no reported mortality.
Interpretation:

Zero-fluoroscopy catheter ablation may be a non-inferior alternative to fluoroscopy-guided procedures, offering similar outcomes while eliminating radiation exposure.

Limitations:
  • Observational design of included studies.
  • Variability in follow-up duration.
  • Heterogeneity in procedural techniques and operator experience.
  • Inconsistent differentiation of arrhythmia subtypes or etiologies.
Conclusion:

Zero-fluoroscopy catheter ablation has demonstrated non-inferiority as a treatment option for ventricular arrhythmia ablation.

Original Source(s)

Zero-Fluoroscopy May Match Standard VA Ablation

  • by Andrea Surnit

  • May 11, 2026

Related Content

Synthetic Echo Motion May Aid ECG Risk Modeling

An ensemble electrocardiogram model classified derived diastolic dysfunction risk phenotypes and stratified heart failure–related death risk across external cohorts, according to findings presented at ASE 2026.

Medical Oddities: Gummies Good for the Gums

From gummies to hookworms, trackers to vibrating pills, medicine took some unexpected turns this week.

FDA Approves Low-Dose Macrocyclic Contrast Agent for MRI

The macrocyclic gadolinium-based contrast agent has a recommended dose of 0.01 mmol/kg actual body weight.